GlassScriptPhysician profile
Joshua David Greenlee
NPI 1801238480
$5,461.63
in general payments reported to CMS, 2019-2025
23 companies · $718 in 2025
The $718 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $348 · 2021: $1,674 · 2022: $729 · 2023: $866 · 2024: $611 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.95 |
| Education | $197.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,867.05 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Mallinckrodt Hospital Products INC. | $607.73 | 2021-2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $423.15 | 2019-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $302.49 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $283.26 | 2019-2023 | Cequa |
| Lkc Technologies, INC. | $271.79 | 2024-2025 | |
| Kala Pharmaceuticals, INC. | $252.80 | 2021-2022 | |
| Allergan, INC. | $219.59 | 2019-2022 | |
| Coopervision INC. | $214.59 | 2019-2024 | Myday Contact Lens |
| Abbvie INC. | $196.49 | 2022-2025 | |
| Oyster Point Pharma, INC. | $183.41 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $124.74 | 2021 | |
| Horizon Therapeutics Plc | $115.20 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $97.44 | 2024 | |
| Bausch & Lomb Americas INC. | $80.25 | 2022-2025 | Xiidra, Miebo, Vyzulta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $45.46 | 2021-2024 | |
| Optos, INC. | $41.41 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.67 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $25.10 | 2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $20.75 | 2022 | |
| Sight Sciences, INC. | $19.72 | 2024 | Tearcare System |
| Shire North American Group INC | $18.80 | 2019 | |
| Maculogix, INC. | $14.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Greenlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.